Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

被引：23
|
作者：
Girgis, Suzette [1 ,3 ]
Lin, Shun Xin Wang [1 ]
Pillarisetti, Kodandaram [1 ]
Verona, Raluca [1 ]
Vieyra, Diego [1 ]
Casneuf, Tineke [2 ]
Fink, Damien [1 ]
Miao, Xin [1 ]
Chen, Yang [1 ]
Stephenson, Tara [1 ]
Banerjee, Arnob [1 ]
Hilder, Brandi W. [1 ]
Russell, Jeffery [1 ]
Infante, Jeffrey [1 ]
Elsayed, Yusri [1 ]
Smit, Jennifer [1 ]
Goldberg, Jenna D. [1 ]
机构：
[1] Janssen Res & Dev LLC, Spring House, PA USA
[2] Janssen Res & Dev LLC, Beerse, Belgium
[3] Janssen Res & Dev, 920 Route 202, Raritan, NJ 08869 USA
来源：
BLOOD ADVANCES | 2023年 / 7卷 / 04期
关键词：
CELL MATURATION ANTIGEN; BONE-MARROW; SURVIVAL;
D O I：
10.1182/bloodadvances.2022007625
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：644 / 648
页数：5
相关论文
共 50 条
  • [1] Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
    Cohen, Yael C.
    Magen, Hila
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Ocio, Enrique M.
    Yoon, Sung-Soo
    Chu, Michael P.
    Rodriguez-Otero, Paula
    Avivi, Irit
    Quijano Carde, Natalia A.
    Kumar, Ashwini
    Krevvata, Maria
    Peterson, Michelle R.
    Di Scala, Lilla
    Scott, Emma
    Hilder, Brandi
    Vanak, Jill
    Banerjee, Arnob
    Oriol, Albert
    Morillo, Daniel
    Mateos, Maria-Victoria
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (02): : 138 - 149
  • [2] Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.
    Girgis, Suzette
    Xin, Shun
    Lin, Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi
    Russell, Jeffery Scott
    Smit, Jennifer
    Goldberg, Jenna D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab
    Girgis, Suzette
    Lin, Shun Xin Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi
    Russell, Jeffery
    Smit, Jennifer
    Goldberg, Jenna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S39 - S40
  • [4] Teclistamab in Relapsed or Refractory Multiple Myeloma
    Hindie, Elif
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (18): : 1721 - 1723
  • [5] Teclistamab in Relapsed or Refractory Multiple Myeloma
    Moreau, Philippe
    Garfall, Alfred L.
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Delforge, Michel
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Lin, Shun X. W.
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita
    Usmani, Saad Z.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (06): : 495 - 505
  • [6] Teclistamab for relapsed refractory multiple myeloma patients on dialysis
    Lebreton, P.
    Lachenal, F.
    Bouillie, S.
    Pica, G. M.
    Aftisse, H.
    Pascal, L.
    Montes, L.
    Macro, M.
    Johnson, N.
    Harel, S.
    Fernandez, M.
    De Renzis, B.
    Lioure, B.
    Lazareth, A.
    Javelot, M.
    Louni, C.
    Huart, A.
    Perrot, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 2077 - 2079
  • [7] Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma
    Moore, Donald C.
    Granger, Katelynn
    Hill, Hailey
    Karabinos, Allison
    Davis, James A.
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (06) : 197 - 200
  • [8] Ambulatory teclistamab administration in patients with relapsed/refractory multiple myeloma
    Tabbara, Nadeem
    Singel, Michael
    Allen, Natalie
    Mooney, Kathy
    Shedeck, Audra
    Zukas, Amber
    Campion, Kate
    Sollenberger, Callan
    Gocke, Christian Burris
    Ali, Syed Abbas
    Huff, Carol Ann
    Imus, Philip H.
    Waheed, Sarah
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Use of Baseline Inflammatory Markers to Predict Toxicities Among Relapsed/Refractory Multiple Myeloma Patients Receiving Ambulatory Teclistamab and Talquetamab
    Tabbara, Nadeem
    Singel, Michael
    Allen, Natalie
    Shedeck, Audra
    Mooney, Kathy
    Campion, Kathryn
    Raymond, Callan
    Sabirzhanova, Inna
    Anderson, Karen
    Waheed, Sarah
    Huff, Carol Ann
    Ali, Syed Abbas
    Gocke, Christian B.
    Imus, Philip
    BLOOD, 2024, 144 : 7232 - 7233
  • [10] Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab
    Chari, Ajai
    Krishnan, Amrita
    Rasche, Leo
    Ye, Jing Christine
    Garfall, Alfred
    Popat, Rakesh
    Lipe, Brea
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara
    Tomlinson, Chalmer
    Hilder, Brandi
    Tolbert, Jaszianne
    Renaud, Thomas
    Smit, M. Damiette
    Gray, Kathleen
    Kane, Colleen
    Heuck, Christoph
    van de Donk, Niels W. C. J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10): : 665 - +
12345